Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
493.84
+1.37 (0.28%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Vertex Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
126,957103,707104,84974,12755,83461,457
Upgrade
Market Cap Growth
-1.09%-1.09%41.44%32.76%-9.15%9.16%
Upgrade
Enterprise Value
117,48394,25391,96565,18149,75055,853
Upgrade
Last Close Price
493.84402.70406.89288.78219.60236.34
Upgrade
PE Ratio
--28.9722.3123.8422.66
Upgrade
Forward PE
27.5222.6624.4418.8316.4221.78
Upgrade
PS Ratio
11.569.4110.628.307.379.90
Upgrade
PB Ratio
7.736.325.965.335.537.08
Upgrade
P/TBV Ratio
8.767.156.706.076.428.44
Upgrade
P/FCF Ratio
--31.4218.8923.1820.53
Upgrade
P/OCF Ratio
--29.6417.9521.1218.89
Upgrade
PEG Ratio
0.861.211.920.581.621.06
Upgrade
EV/Sales Ratio
10.668.559.327.306.579.00
Upgrade
EV/EBITDA Ratio
24.6119.7420.5414.4012.3817.66
Upgrade
EV/EBIT Ratio
25.5820.5221.3514.8912.7818.29
Upgrade
EV/FCF Ratio
--27.5616.6120.6618.66
Upgrade
Debt / Equity Ratio
0.110.110.050.070.100.11
Upgrade
Debt / EBITDA Ratio
0.360.360.180.200.240.30
Upgrade
Debt / FCF Ratio
--0.240.230.400.32
Upgrade
Asset Turnover
0.490.490.480.570.600.62
Upgrade
Inventory Turnover
5.145.147.388.878.9710.62
Upgrade
Quick Ratio
2.172.173.604.464.044.02
Upgrade
Current Ratio
2.692.693.994.834.464.33
Upgrade
Return on Equity (ROE)
-3.15%-3.15%22.99%27.67%24.93%36.71%
Upgrade
Return on Assets (ROA)
12.68%12.68%13.17%17.33%19.32%19.02%
Upgrade
Return on Capital (ROIC)
15.71%15.71%16.22%21.15%23.51%23.29%
Upgrade
Return on Capital Employed (ROCE)
24.20%24.20%22.50%28.40%34.50%30.90%
Upgrade
Earnings Yield
-0.42%-0.52%3.45%4.48%4.20%4.41%
Upgrade
FCF Yield
-0.62%-0.76%3.18%5.29%4.31%4.87%
Upgrade
Buyback Yield / Dilution
1.00%1.00%-0.54%0.31%1.33%-1.04%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q